Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Optimal length of antiviral therapy in patients with hepatitis C virus genotypes 2 and 3: a meta-analysis.

Antiviral therapy - 1 Jan 2009

Slavenburg Serena, Weggelaar Ines, van Oijen Martijn G H, Drenth Joost P H

Abstract excerpt

BACKGROUND: Current guidelines recommend a duration of 24 weeks of treatment with pegylated interferon and ribavirin for patients infected with chronic hepatitis C virus (HCV) genotypes 2 and 3. Several trials investigated whether shorter treatment duration is equally effective in achieving sustained virological response (SVR). Our aim was to determine the optimal length of treatment in patients with HCV...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Administration Schedule
Share to Drug Therapy, Combination

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Interferon-alpha

Share to Interferon alpha-2

Share to Interferons

Share to Polyethylene Glycols

Share to Randomized Controlled Trials as Topic

Share to Ribavirin

Source

Identifiers

PMID: 20032543
DOI: 10.3851/IMP1464

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Optimal length of antiviral therapy in patients with hepatitis C virus genotypes 2 and 3: a meta-analysis.PMID 20032543Read ↗

What is the optimal duration of therapy in patients with hepatitis C genotype 2 or 3 infection?: a review.Semantic proximity Read ↗

Tailoring treatment duration to 12 to 16 weeks in hepatitis C genotype 2 or 3 with rapid virologic response: systematic review and meta-analysis of randomized controlled trials.Semantic proximity Read ↗

Randomised clinical trial: the efficacy of treatment, guided by a shorter duration of response, using peginterferon alfa-2a plus ribavirin for hepatitis C virus other than genotypes 2 or 3.Semantic proximity Read ↗

Impact of shorter duration of treatment on virological response rate in genotype 2 or 3 chronic hepatitis C virus infection.Semantic proximity Read ↗

Short-term therapy for patients with hepatitis C virus genotype 2 or 3 infection.Semantic proximity Read ↗

Individualizing treatment duration in hepatitis C virus genotype 2/3-infected patients.Semantic proximity Read ↗

Optimizing the treatment of chronic hepatitis due to hepatitis C virus genotypes 2 and 3: a review.Semantic proximity Read ↗

Shortened treatment duration in treatment-naive genotype 1 HCV patients with rapid virological response: a meta-analysis.Semantic proximity Read ↗

Short versus standard treatment with pegylated interferon alfa-2A plus ribavirin in patients with hepatitis C virus genotype 2 or 3: the cleo trial.Semantic proximity Read ↗

Response-guided peg-interferon plus ribavirin treatment duration in chronic hepatitis C: meta-analyses of randomized, controlled trials and implications for the future.Semantic proximity Read ↗

Meta-analysis: the outcome of anti-viral therapy in HCV genotype 2 and genotype 3 infected patients with chronic hepatitis.Semantic proximity Read ↗

Optimal therapy in hepatitis C virus genotypes 2 and 3 patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.